

Frequency of Restrictive Pulmonary Function in Type 2 Diabetes Mellitus

Muhammad Farooq,¹ Sheraz Saleem,² Imtiaz Hussain,³ Sajid Abaidullah⁴

Abstract

Objectives: The aim of this study was to determine the frequency of restrictive pulmonary dysfunction in type 2 diabetic patients.

Study Design: Cross – sectional Study.

Setting: Outpatient clinic of Department of Medicine, King Edward Medical University, Lahore.

Subject and Methods: One hundred and seventy patients of Type 2 Diabetes Mellitus, presented in outpatient department of Mayo Hospital, Lahore with inclusion and exclusion criteria were included in the study. After taking informed consent, pulmonary function tests were performed. Patients were explained about the risks and benefits while their identity was

kept confidential. The demographic information of the patients like name, age, sex, height and weight were collected. Digital spirometer was used to perform pulmonary function tests. FEV₁ / FVC Ratio more than 80% or normal, was considered as restrictive defect and Ratio less than 80%, was considered as obstructive defect. All collected information was recorded on pre-designed Performa (attached). Effect modifying factors like duration of type 2 diabetes mellitus and smoking status (smoker and non smoker) were addressed through data stratification.

Results: In this study, we included one hundred and seventy type 2 diabetic patients. The mean age was 54.32 ± 19.08 years. There were 122 (71.8%) males and 48 (28.2%) females. The mean height was 161.59 cm. The mean FVC was 107.78 ± 20.31 . The mean FEV₁ was 94.09 ± 27.72 . The mean FEV₁ / FVC% was 104.762 ± 24.93 . In 28 (16.5%) cases restrictive pathology was observed, 3 (1.8%) cases had obstructive pathology and 139 (81.8%) cases had normal lung function tests.

Conclusion: In this study we concluded that the target organ for diabetic injury was lung. It was responsible for restrictive diseases of lung. More research work required to rule out pathophysiologic mechanisms and clinical significance.

Key Words: Diabetes Mellitus, Pulmonary function test, Restrictive pulmonary dysfunction.

Date of Submission 15-9-2015

Date of Acceptance for Publication 3-5-2016

Conflict of Interest: None

Funding Source: None

Farooq M.¹
Registrar, North Medical Ward, Mayo Hospital, Lahore

Saleem S.²
Assistant Professor of Medicine
Sargodha Medical College, Sargodha

Hussain I.³
Senior Registrar, Dept of Surgery
Sir Ganga Ram Hospital, Lahore

Sajid Abaidullah S.⁴
Professor of Medicine, KEMU/ Mayo Hospital, Lahore

Introduction

Diabetes mellitus is a metabolic disorder because of insulin deficiency, inappropriate hyperglycemia generates or may be because of insulin resistance inside the body and insufficient insulin secretion to recompense with the body glucose. Type 2 Diabetes mellitus is

dominant type and resulting from insulin resistance with compensatory insulin secretion dysfunction. T₂DM is common in > 90% cases.¹

In recent year it has been noticed with the evidences that pulmonary function of T₂DM patients is reduced. Pulmonary factors associated with vital capacity warrant consideration as potential risk factors for insulin resistance and T₂DM.² The Fremantle Diabetes Study showed that in start of study, among 125 T₂DM candidates, 29 candidates had FEV₁ < 70% of predicted value and FVC < 80% of predicted value without previously documented pulmonary dysfunction.³

Lung functions are compromised in patients with T₂DM like decrease in FVC, FEV₁ and PEF as compared to non-diabetics. Stratification of results by duration of disease shows a dose – response effect on lung function parameters.⁴ Patients with T₂DM have significantly lower FVC and FEV₁ than those without T₂DM. FVC decreased in T₂DM patients faster than non diabetics.⁵

Chronic complications of T₂DM are decreased lung volumes and airflow limitation severity of which correlate with the exposure of glycemic level. After adjusting other risk factors, airflow restriction is predictor of death in T₂DM.³ Expression of adhesion molecules increases due to hyperglycemia in T₂DM patients. Lower pulmonary volumes in T₂DM patients are due to compromised pulmonary microvasculature. Sensitive markers for endothelial activation and damage is adhesion molecules appearance in patients with T₂DM.⁶

Pulmonary function tests have been proved to be affected by T₂DM. However no research work has been done in Pakistan so far. My study would like to record the frequency of pulmonary dysfunction in patients with T₂DM, so that early pulmonary function changes can be picked up and thus improve the patient care by strict glycemic control. We can reduce morbidity in patients with T₂DM due to lung dysfunction by assuming lung as another target organ.

Material and Methods

This cross sectional study was conducted at Department of Medicine, King Edward Medical University Lahore from 01-02-2015 to 31-07-2015. One hundred and seventy non smoker ages 38 – 70 years both male and female with type 2 Diabetes Mellitus, fulfilling the inclusion and exclusion criteria were included in the study through diabetic clinic of Mayo Hospital Lahore.

Smokers or patients with a history of acute or chronic respiratory disease, history of cirrhosis of liver and autoimmune diseases, history of occupational exposure like petrol pump workers or working in chemical or wood factory, neuromuscular or cardiovascular diseases or kyphoscoliosis, pectus excavatum and pectus carinatum and morbidly obese patients with BMI > 30 kg/m² or patients having complaints of cough, sputum, or dyspnea were excluded. After taking informed consent, pulmonary function tests were performed. Patients were explained about the risks and benefits while their identity was kept confidential. The demographic information of the patients like name, age, sex, height and weight were collected. If FEV₁ / FVC Ratio is more than 80% or normal it was considered as restrictive defect and if this Ratio is less than 80% it was considered as obstructive defect. All information was recorded on pre-designed Performa. All Data analyzed by using SPSS version 21.0 for windows. Variable like age was given as mean and standard deviation. Variables like sex and pulmonary dysfunction (restrictive) were given as frequency and percentage.

Results

The study included one hundred and seventy patients with the mean age of 54.32 ± 19.08 years. There were about 122 (71.8%) males and 48 (28.2%) females as shown in Table 1. The mean height was 161.59 cm.

Table 1: Age distribution of patients according to Gender; (n = 170).

Gender	Mean Age (Years)	SD	Minimum	Maximum
Male	54.30	6.49	38	70
Female	54.39	6.52	40	70

Table 2: Spirometry results and gender; (n = 50).

S. #	Parameters	Males	Females
1.	FVC liter / minute	109.28 ± 20.22	106.28 ± 20.4
2.	FEV ₁ liter/ minute	94.5 ± 28.07	93.06 ± 27.08
3.	FEV ₁ / FVC %	105.36 ± 24.46	103.25 ± 26.29

The mean FVC was $106.28 \pm 20.4\%$. The mean FEV₁ was $94.09 \pm 27.72\%$. The mean FEV₁ / FVC% was 104.762 ± 24.93 . Spirometry results according to gender are given in Table 2. In 28 (16.5%) cases, restrictive pathology was observed, 3 (1.8%) cases had obstructive pathology and 139 (81.8%) cases had normal lung function tests as shown in Figure 2.




Figure 1: Pie Graph showing Gender Distribution.




Figure 2: Pulmonary Dysfunction in Type II Diabetes Patients.

Discussion

Type 2 diabetes mellitus (T₂DM) is a multisystem syndrome that affects almost every part of the body. It is base of all other associated problems of the human body. It is highly prevalent and become an important problem to be considered and has been widely discussed. T₂DM also disturb the respiratory system but until now, very minor research work has been done in this regard.

The cross – sectional studies have shown that vital capacity is lower in T₂DM as compared to non-diabetics.⁷ Our study included 170 T₂DM patients, 16.5% were found to have restrictive pathology, 1.8% had obstructive pathology and 81.8% had normal lung function tests.

The results are similar to previously published data. Atherosclerosis Risk in Communities (ARIC)⁸ study of adults ages 45 – 64, with hypothesis that T₂DM is associated with reduced pulmonary function parameters. In cross – sectional analysis, middle – age T₂DM patients have significantly lower pulmonary function parameters than predicted. These associations are categorized by fasting glucose, HbA_{1c}, duration of diabetes and treatment. In prospective analysis, FVC decreased faster in T₂DM patients as compared to non-diabetics. These correlations were independent of risk factors for lung function dysfunctions. This study, showed annual decrease of FVC by 58 ml/year.

Results are consistent with cross – sectional studies which also have shown that diabetic patients have reduced FEV₁ and FVC as compared to non-diabetics^{9,10} with respect to the duration of diabetes. Insulin treatment becomes mandatory, when diabetic patients have co-morbidities. While non diabetic patients have lower FVC and FEV₁ due to high fasting glucose, hyperinsulinemia and insulin resistance.

Lange et al,¹¹ followed 506 Danish adults in the Copenhagen City Heart Study for 15 years. Diabetic patients had lower FVC and FEV₁ with difference of > 8% in FVC between diabetics and non-diabetics. However, Diabetics had declined FVC 24 ml/year in females and 39 ml/year in males.

Davis et al,¹² followed 125 Australian T₂DM patients for duration of 7 years. FVC and FEV₁ declined at annual rates of 68 and 71 ml/year, respectively. FVC and FEV₁ were declined in patients with higher baseline HBA_{1c} with no non-diabetic control group.

Litonjua et al,¹³ conducted a case-control study in 352 patients with T₂DM and 352 controls. This study showed that T₂DM patients had lower FEV₁ and FVC. They had only 5.4 ml/year decline after diagnosis of diabetes as compared to non-diabetics.

Primary mechanism lung dysfunction in diabetes remains unclear, Glycosylation of chest wall, thickening of basal lamina,¹⁴ increased susceptibility to respiratory infections and bronchial tree proteins were mechanism suggested in previous studies. However, hyperglycemia, inflammation and diabetes – related oxidative stress have association with muscular dysfunction.¹⁵ The pro-inflammatory master regulator

molecules could mediate these effects which is further mediated by hyperglycemia.^{16,17}

Other studies of pulmonary dysfunction in the pre-diabetic cases obscure causal extrapolations. Recent studies showed that compromised lung function is an independent factor of T₂DM incidence.¹⁸ Cross sectional studies showed significant association in diabetes and lung functions as compared to prospective studies. These results showed that abnormalities in lung function precede diabetes and continue after onset of diabetes.

In a study conducted by Sharma B et al,²⁰ a mixed restrictive – obstructive pattern of pulmonary dysfunction has been observed in T₂DM patients which become more severe with course / duration of the disease and poor glycemic control. Strict glycemic control over 12 weeks is not adequate to progress this pulmonary dysfunction. Losartan (diabetes medication) with strict glycemic control does not improve the pulmonary function. Pulmonary dysfunction should be considered as a precise derangement induced by T₂DM. Further studies may elucidate whether this should be included as a long term complication of T₂DM. The role of strict glycemic control and losartan therapy on pulmonary function in diabetics with incipient nephropathy is another interesting aspect and needs further studies.

In a study done by Nakajima K et al,²¹ the most believable factor for the association between Restrictive Pattern and Metabolic syndrome is insulin resistance, an essential component that aggravates metabolic abnormalities. The association between pulmonary dysfunction and insulin resistance, and insulin deficiency has been verified by many investigators over several decades.¹⁵⁸⁻²¹

This study has shown lung dysfunction, especially reduced vital capacity found in T₂DM patients. Further research work required for pathophysiologic mechanisms and clinical importance of this association. Moreover, physicians must pay close attention to T₂DM patients regarding their pulmonary functions. Cross sectional studies have been conducted in T₂DM with respect to their pulmonary functions till today. Some T₂DM patients have shown abnormalities of pulmonary function parameters, however more information of the association required to be sought out. The influence of duration of diabetes and glycemic control have major role in the development of restrictive pulmonary dysfunction through randomized trials.

Conclusion

In this study we conclude that the target organ for diabetic injury is lung. It is responsible for restrictive diseases of lung. More research work required to rule out pathophysiologic mechanisms and clinical significance.

References

1. Masharani U. Diabetes mellitus and hypoglycemia. Current medical diagnosis and treatment. 47th ed. New York: Mc Graw Hill, 2008; p. 1032-73.
2. Yeh HC, Punjabi NM, Warisq NY, Parkow JS, Duncan BB, Brancati FL. Vital capacity as predictor of incident type 2 diabetes. *J Diabetes care*, 2005; 28: 1472-9.
3. Davis WA, Kneuman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary functions in type 2 diabetes. *J Diabetes care*, 2004; 27: 752-7.
4. Mew SA, Al-Drees AM, Arif, Al-Rubean K. Lung functions in Saudi type 2 diabetic patients. *J Saudi Med*. 2006; 27: 338-43.
5. Yeh HC, Punjabi NM, Wang NY, Pankaw JS, Duncan BB, Cox CE, et al. Cross sectional and prospective study of lung functions in adults with type 2 diabetes; the artroeclerosis risk in communities (ARIC) study. *Diabetes care*, 2008; 31: 741-6.
6. Boulbou MS, Gourgoulanis KI, Petinaki EA, Klisiaris VK, Maniatis AN, Molyvdas PA. Pulmonary function and circulating adhesion molecules in patients with diabetes mellitus. *Can Respir J*. 2003; 10: 259-64.
7. Marvisi M, Bartolini L, del Borrello P, Brianti M, Marani G, Guariglia A, Cuomo A: Pulmonary function in non-insulin – dependent diabetes mellitus. *Respiration*, 2001; 68: 268–72.
8. Yeh H-C, Punjabi NM, Wang N-Y, Pankow JS, Duncan BB, Cox CE et al. Cross – sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. *Diabetes Care*, 2008; 31: 741-6.
9. Lawlor DA, Ebrahim S, Smith GD: Associations of measures of lung function with insulin resistance and type 2 diabetes: findings from the British Women's Heart and Health Study. *Diabetologia*. 2004; 47: 195–203.
10. Lange P, Parner J, Schnohr P, Jensen G: Copenhagen City Heart Study: longitudinal analysis of ventilatory capacity in diabetic and non-diabetic adults. *Eur Respir J*. 2002; 20: 1406–12.
11. Borch – Johnson K, for DECODE study group, on behalf of the European Diabetes Epidemiology Study Group. “Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes?” Re-analysis of European Epidemiological Data. *Br Med J*.

- 1998; 32: 317-75.
12. Vogt BW, Schleicher ED, Wieland OH. e-amino-lysine – bound glucose in human tissue obtained at autopsy. *Diabetes*, 1982; 31: 1123-27.
13. Litonjua AA, Lazarus R, Sparrow D, Demolles D, Weiss ST: Lung function in type 2 diabetes: the Normative Aging Study. *Respir Med*. 2005; 99: 1583–90.
14. Weynand B, Jonckheere A, Frans A, Rahier J: Diabetes mellitus induces a thickening of the pulmonary basal lamina. *Respiration*, 1999; 66: 14–9.
15. Niedowicz DM, Daleke DL: The role of oxidative stress in diabetic complications. *Cell Biochem Biophys*. 2005; 43: 289–330.
16. Patti ME: Gene expression in the pathophysiology of type 2 diabetes mellitus. *Curr Diab Rep*. 2004; 4: 176–81.
17. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. *Circulation*, 2005; 111: 1448–54.
18. Engstrom G, Janzon L: Risk of developing diabetes is inversely related to lung function: a population – based cohort study. *Diabet Med*. 2002; 19: 167–70.
19. Cefalu WT: Concept, strategies, and feasibility of non-invasive insulin delivery. *Diabetes Care*, 2004; 27: 239–46.
20. Sharma B, Daga MK, Tiwari N, Kaushik M. Pulmonary Dysfunction in Type 2 Diabetes Mellitus Patients With Incipient Diabetic Nephropathy and Effect of Glycemic Control and Losartan Therapy on Pulmonary Function, 2003; 124 (4): 162.
21. Nakajima K, Kubouchi Y, Muneyuki T, Ebata M, Eguchi S, Munakata H. A Possible Association between Suspected Restrictive Pattern as Assessed by Ordinary Pulmonary Function Test and the Metabolic Syndrome. *Am. J. Epidemiol.*, December 15, 2008; 158 (12): 1171–1181.